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Abstract 1 
Background  2 
Additional vector control tools (VCTs) are needed to supplement insecticide-treated nets (ITNs) and 3 
indoor residual spraying (IRS) to achieve malaria elimination in many settings. To identify options for 4 
expanding the malaria vector control toolbox, we conducted a systematic review of the availability and 5 
quality of the evidence for 21 malaria VCTs, excluding ITNs and IRS.  6 
Methods  7 
Six electronic databases and grey literature sources were searched from January 1, 1980 to September 28, 8 
2015 to identify systematic reviews, Phase I-IV studies, and observational studies that measured the effect 9 
of malaria VCTs on epidemiological or entomological outcomes across any age groups in all malaria-10 
endemic settings. Eligible studies were summarized qualitatively, with quality and risk of bias 11 
assessments undertaken where possible. Of 17,912 studies screened, 155 were eligible for inclusion and 12 
were included in a qualitative synthesis.  13 
Results 14 
Across the 21 VCTs, we found considerable heterogeneity in the volume and quality of evidence, with 15 
seven VCTs currently supported by at least one Phase III community-level evaluation measuring 16 
parasitologically-confirmed malaria incidence or infection prevalence (insecticide-treated clothing and 17 
blankets, insecticide-treated hammocks, insecticide-treated livestock, larval source management (LSM), 18 
mosquito-proofed housing, spatial repellents, and topical repellents). The remaining VCTs were 19 
supported by one or more Phase II (n=13) or Phase I evaluation (n=1). Overall the quality of the evidence 20 
base remains greatest for LSM and topical repellents, relative to the other VCTs evaluated, although 21 
existing evidence indicates that topical repellents are unlikely to provide effective population-level 22 
protection against malaria.  23 
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Conclusions  24 
Despite substantial gaps in the supporting evidence, several VCTs may be promising supplements to ITNs 25 
and IRS in appropriate settings. Strengthening operational capacity and research to implement 26 
underutilized VCTs, such as LSM and mosquito-proofed housing, while expanding the evidence base for 27 
promising supplementary VCTs that are locally tailored, should be considered central to global malaria 28 
elimination efforts.  29 
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Introduction 30 
Great advances have been made in malaria control and elimination, with a 37% global decline in malaria 31 
incidence during 2000-2015.1,2 New targets include the elimination of malaria from at least 35 countries 32 
between 2015 and 2030,1 with renewed calls for eradication within a generation.3 In sub-Saharan Africa 33 
(SSA), vector control with insecticide-treated nets (ITNs) and indoor residual spraying (IRS) has averted 34 
an estimated 524 million malaria cases since 2000.2 However, there remain important obstacles to 35 
achieving and sustaining elimination, including operational inefficiencies that lead to low effective 36 
coverage,4 insecticide resistance,5 and residual transmission mediated by mosquito behaviours such as 37 
outdoor biting and resting, feeding upon animals, and early exit from houses immediately after entering,  38 
which are not effectively targeted by ITNs and IRS.6,7  39 
 40 
To achieve malaria elimination goals in the face of such challenges, what evidence-based vector control 41 
tools (VCTs) can national malaria control and elimination programs access today or within the next 42 
decade, to supplement ITNs and IRS? To date, ITNs and IRS are the only VCTs to have been 43 
recommended for wide-scale implementation by the World Health Organization (WHO), while larval 44 
source management (LSM) and personal protection measures against mosquitoes are recommended in 45 
some settings.1 Recognising the need for additional VCTs, WHO recently established mechanisms for 46 
expedited vector control recommendations, including new technical expert panels,8 and the recently-47 
formed Innovation to Impact (I2I) initiative also aims to support VCT development and 48 
implementation.9,10 Here, to guide the identification of promising VCTs to expand the vector control 49 
toolbox for malaria elimination, we conducted a systematic review to collate published and unpublished 50 
evidence on the effect of selected VCTs on confirmed clinical malaria and malaria infection in people of 51 
any ages and on Anopheles-specific entomological outcomes in malaria-endemic regions. This is the first 52 
study to collate systematically the evidence across the spectrum of malaria vector control, excluding ITNs 53 
and IRS. 54 
 55 
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Methods  56 
We conducted a systematic review of the literature to summarize the availability and quality of the 57 
evidence for 21 malaria VCTs, excluding ITNs and IRS (Table 1). We followed guidelines of the 58 
Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) (Additional File 1).11 59 
The candidate VCTs for evaluation were selected through consultation with experts (including a meeting 60 
held on June 1-3, 2015 in San Francisco, US) and the review of policy documents.9,12  61 
 62 
[Insert Table 1 here] 63 
 64 
Eligibility criteria 65 
Studies were included that evaluated any VCT targeting Anopheles mosquitoes in Table 1 and that met 66 
the eligibility criteria described in Table 2. Eligible study designs were categorized as observational, 67 
Phase I, Phase II, or Phase III studies. Observational studies included those with case-control, cohort or 68 
cross-sectional designs. Phase I studies were defined as laboratory assays to determine the mode of 69 
action. Phase II were defined as semi-field, experimental hut, and small-scale field studies, generally with 70 
entomological outcomes. Finally, Phase III studies were defined as trials measuring the efficacy of the 71 
VCT against epidemiological outcomes under optimal conditions.13 72 
 73 
[Insert Table 2 here] 74 
 75 
Search strategy and selection criteria 76 
PubMed; EMBASE; LILACS; the Cochrane Infectious Diseases Group Specialized Register; Cochrane 77 
Central Register of Controlled Trials (CENTRAL), published in The Cochrane Library; and the Meta-78 
Register of Controlled Trials (mRCT) were searched for studies published in English from January 1, 79 
1980 to September 28, 2015 with the search terms described in Additional File 2. Search dates were 80 
restricted because systematic reviews included in this review captured the historical evidence on older 81 
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VCTs, including LSM. Additionally, we searched reference lists of identified studies and contacted 82 
authors and field experts for unpublished data. To identify studies in progress, we searched the 83 
ClinicalTrials.gov registry. YAW and SH independently screened titles and abstracts, followed by full-84 
text screening of relevant studies for eligibility using a standard form in Qualtrics (Qualtrics, Provo, UT). 85 
Disagreements were resolved by LST.  86 
 87 
Data abstraction 88 
Study characteristics (including participants, intervention, control group, outcomes, and sample size, as 89 
applicable) and findings were double-entered into a standard form in Microsoft Excel by YAW and 90 
verified by LST. Since we aimed to assess evidence availability, not VCT efficacy, we did not combine 91 
studies in a meta-analysis. Instead, for each VCT we summarized the current evidence by the number and 92 
type of completed studies and, where possible, stratified this information by outcome. We presented in 93 
tables all eligible studies for every VCT, except for VCTs with a recent (≤5 years old) high-quality 94 
systematic review (Measurement Tool to Assess Systematic Reviews (AMSTAR)14 score ≥50%; see 95 
below), for which we presented only the systematic review.13 96 
 97 
Quality of systematic reviews and risk of bias in Phase III studies 98 
The quality of systematic reviews was assessed using the AMSTAR tool.14 Risk of bias for randomized 99 
controlled trials (RCTs), controlled before-and-after studies (CBA), cross-over studies, and interrupted 100 
time-series studies was assessed using the Effective Practice and Organization of Care (EPOC) tool.15 101 
Risk of bias was not assessed for Phase I, Phase II, or observational studies due to wide heterogeneity in 102 
study designs. We did not perform a statistical test for publication bias because we did not conduct any 103 
meta-analyses. 104 
 105 
Results 106 
7 
 
The search results yielded 17,912 unique studies after removing duplicates (Figure 1). A total of 155 107 
studies met the eligibility criteria and were included in the qualitative synthesis; these were of the 108 
following designs: systematic reviews (n=7); Phase III (n=7), Phase II (n=76), and Phase I (n=54) 109 
experimental studies; and cross-sectional (n=7), case-control (n=3), and cohort (n=1) observational 110 
studies (Figure 2, Additional File 3). Methodological quality was variable across the seven eligible 111 
systematic reviews, with AMSTAR scores ranging from 18% to 100% (Additional File 4A). The 112 
systematic reviews of LSM (n=2), mosquito-proofed housing (n=1), and topical repellents (n=1) were 113 
determined to be of the highest quality (AMSTAR scores ≥50%), while those of spatial repellents (n=2) 114 
and zooprophylaxis (n=1) were judged to be of lower quality. Of the 21 VCTs evaluated, we identified 115 
seven with one or more completed Phase III study, including some that were included in systematic 116 
reviews: LSM, insecticide-treated clothing and blankets, insecticide-treated hammocks, insecticide-117 
treated livestock, mosquito-proofed housing, spatial repellents, and topical repellents; with recent, high-118 
quality systematic reviews available for LSM, mosquito-proofed housing, and topical repellents (Table 3). 119 
 120 
[Insert Figure 1 here] 121 
 122 
[Insert Figure 2 here] 123 
 124 
[Insert Table 3 here] 125 
 126 
VCTs with a recent systematic review 127 
Larval source management (LSM): A 2013 Cochrane review compared biological control with 128 
larvivorous fish to biological control without larvivorous fish.16 No eligible studies included in this 129 
review measured malaria incidence, entomological inoculation rate (EIR), or adult vector density (Table 130 
3). Nine quasi-experimental studies measured larval mosquito density, with variable effects. A second 131 
2013 Cochrane review compared LSM (excluding biological control with larvivorous fish) with no 132 
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LSM.17 Compared to the control, LSM reduced malaria incidence by 74% in two cluster RCTs, but there 133 
was no consistent effect on malaria incidence in three CBA studies. GRADE quality of evidence ranged 134 
from very low to moderate. Parasite prevalence was reduced by 89% in another cluster-RCT and by an 135 
average of 68% in five CBA studies. GRADE quality of evidence was assessed to be moderate for both 136 
subgroups.  137 
 138 
Mosquito-proofed housing: A 2015 systematic review included one Phase III RCT and four observational 139 
studies in a meta-analysis comparing screened with unscreened housing, in which findings on the effect 140 
on clinical malaria, malaria infection, and anaemia in children were inconsistent (Table 3).18 A further 15 141 
observational studies were included in a meta-analysis comparing ‘modern’ housing (e.g. brick or cement 142 
walls and metal roofs) with ‘traditional’ housing (e.g. mud walls, thatched roofs, open eaves, and no 143 
screening).18 Modern housing was associated with a 45-65% lower odds of clinical malaria and 47% 144 
lower odds of malaria infection, compared to traditional housing, although the GRADE quality of 145 
evidence was assessed to be very low. 146 
 147 
Topical repellents: In a systematic review of experimental studies comparing topical repellents with no 148 
repellent or placebo repellents,19 the risk of P. falciparum malaria or infection was reduced by 18% in six 149 
RCTs and one CBA. P. vivax malaria or infection was reduced by 20% in five RCTs and one CBA, 150 
compared to the control, but neither reduction was statistically significant. EPOC risk of bias in the 151 
included studies ranged from low to unclear (Table 3).  152 
 153 
Other VCTs with a Phase III evaluation 154 
Insecticide-treated clothing and blankets: Malaria incidence was measured in two RCTs with low to 155 
moderate risk of bias, where the effect of insecticide-treated clothing and blankets ranged from an 81% 156 
decrease to no effect, compared to the control (Table 3).20,21 Outcomes assessed by the four Phase II 157 
studies included parasite prevalence (n=2) and adult mosquito mortality (n=2) (Additional File 3B).  158 
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 159 
Insecticide-treated hammocks: Malaria incidence and parasite prevalence were measured in two Phase III 160 
RCTs, with EPOC risk of bias for both studies assessed to be low (Table 3). In Venezuela, insecticide-161 
treated hammocks reduced malaria incidence by 56% and parasite prevalence by 83%, compared to the 162 
control,22 and in Vietnam a greater reduction in malaria incidence and parasite prevalence was observed 163 
in the intervention arm than in the control (footnote to Table 3).23 One Phase II study measured adult An. 164 
gambiae mortality, hut entry, and blood feeding inhibition (Additional File 3C).  165 
 166 
Insecticide-treated livestock: Malaria incidence and parasite prevalence were measured in one Phase III 167 
cross-over study, with EPOC risk of bias assessed to be moderate, in which insecticide-treated livestock 168 
reduced malaria incidence by 31-56% and parasite prevalence by 40-54% compared to the control, though 169 
the effect was not consistently significant (Table 3).24 Entomological outcomes measured in five Phase II 170 
studies included adult mosquito mortality and blood feeding preference (Additional File 3C).  171 
 172 
Spatial repellents: Two systematic reviews included laboratory and Phase II field studies only, with no 173 
meta-analyses (Table 3).25,26 No eligible studies measured the effect of spatial repellents on malaria 174 
incidence. Parasite prevalence was measured in two RCTs, with the EPOC risk of bias assessed to be low 175 
for both studies, and in one cross-sectional study. In the RCTs, transfluthrin coils reduced parasite 176 
prevalence by 77% compared to long-lasting insecticide-treated nets (LLINs) alone and by 94% when 177 
combined with LLINs, compared to no intervention in China;27 metofluthrin mosquito coils reduced 178 
parasite prevalence by 52% compared to a placebo in Indonesia.28 Entomological outcomes measured in 179 
23 Phase II studies and one Phase I study included human biting rate (HBR), adult mosquito mortality, 180 
and repellency (Additional File 3C).  181 
 182 
VCTs with no Phase III evaluation 183 
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Fourteen VCTs had Phase I, II, and/or observational evidence only: adult sterilization by contamination, 184 
attractive toxic sugar baits (ASTB), other attract-and-kill mechanisms, biological control of adult vectors, 185 
eave tubes and eave baffles, endectocide administration in humans, endectocide administration in 186 
livestock, genetic modification, insecticide-treated durable wall linings, insecticide-treated fencing, 187 
larvicide application by autodissemination, push-pull systems, space spraying (ground application), and 188 
zooprophylaxis (Figure 2, Additional File 3C, Additional File 3D).  For these VCTs we included a total of 189 
103 studies, comprising 42 Phase II, 51 Phase I, and 10 observational studies. All VCTs had at least one 190 
eligible Phase II study, except endectocide administration in humans. Three VCTs had at least one 191 
eligible observational study: endectocide administration in humans, spatial repellents, and 192 
zooprophylaxis. For zooprophylaxis, we also identified one systematic review (AMSTAR score 18%), 193 
which reported no meta-analysis.29 Entomological outcomes were measured for all VCTs, while 194 
epidemiological outcomes were measured for two VCTs only (space spraying and zooprophylaxis). 195 
 196 
Discussion 197 
To strengthen malaria vector control and maintain progress towards elimination, additional malaria vector 198 
control tools are needed to supplement ITNs and IRS. In this systematic review assessing the availability 199 
and quality of evidence for 21 supplementary VCTs, we included 155 studies dating from January 1, 1980 200 
to September 28, 2015. This is the first study to collate evidence systematically across the malaria vector 201 
control toolbox beyond ITNs and IRS. Our study highlights the expanding pipeline of research into 202 
supplementary VCTs, while identifying substantial heterogeneity in the availability and quality of the 203 
evidence required by WHO to provide normative guidance on implementation (i.e. standardized 204 
epidemiological data from Phase III trials in multiple settings).9,30    205 
 206 
For each VCT, we summarized the current evidence by the number and quality of studies and stratified 207 
this information by outcome where possible. Within this framework, the evidence base was the most 208 
extensive for LSM and topical repellents, which both have multiple published Phase III evaluations and 209 
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recent systematic reviews assessed to be of high methodological quality. While the evidence for LSM was 210 
assessed to be of very low to moderate quality,17 combinations of larviciding and environmental 211 
management have been effective in reducing malaria transmission in certain eco-epidemiological settings 212 
in Africa and Asia and larviciding has been recommended by WHO as a supplementary intervention in 213 
SSA since 2013.2 This recommendation is limited to discrete settings where habitats are relatively ‘few, 214 
fixed, and findable’; far narrower than settings in high-income countries where larviciding is used 215 
routinely and successfully for mosquito and disease control.2 In contrast, the evidence for topical 216 
repellents is of relatively high quality19 but indicates that they are unsuitable as a large-scale public health 217 
intervention, although they can provide individual protection against mosquitoes.19 We identified five 218 
further VCTs with at least one Phase III evaluation with epidemiological outcomes: insecticide-treated 219 
clothing and blankets, insecticide-treated hammocks, insecticide-treated livestock, mosquito-proofed 220 
housing, and spatial repellents. These VCTs offer additional options for supplementing ITNs and IRS, 221 
often with complementary modes of action. Further Phase III community level trials will help to clarify 222 
their roles in malaria vector control in different epidemiological settings.6,31,32 223 
 224 
Our assessment of evidence was based on study design and outcomes, but in the future it may be 225 
necessary to consider evidence complementary to standard epidemiological assessments.33 First, making 226 
recommendations across diverse transmission settings and local vector ecologies is difficult. Although 227 
Cochrane reviews remain the gold standard in evidence-based policy, it is often inappropriate to combine 228 
findings from studies across different eco-epidemiological settings when VCT efficacy is tied to local 229 
transmission ecology.16,17 Second, some emerging VCTs remain years away from accumulating a full 230 
dossier of epidemiological evidence, and although further Phase III studies are planned,34 nearing 231 
completion,35 or recently concluded,36 we identified fourteen VCTs for which no Phase III 232 
epidemiological data were available within the search dates. Demonstrating protection against disease 233 
and/or infection is critical before any VCTs can be recommended for large-scale deployment.13 However, 234 
in some circumstances evidence of effect might be built by adopting underutilized VCTs as 235 
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supplementary interventions within a ‘learning-by-doing’ framework. This iterative approach involves the 236 
incorporation of rigorous monitoring and evaluation of epidemiological and entomological outcomes in 237 
control and intervention areas, to support the gradual scale-up of additional VCTs within existing 238 
programme infrastructure, such as through adaptable Phase IV effectiveness studies.6,13,37 For example, 239 
while only one RCT of house screening for malaria control has been completed,38 a large body of 240 
observational evidence suggests that screened housing is associated with reduced malaria risk and 241 
national malaria control programs are encouraged to explore opportunities to build ‘healthier’ housing.39  242 
 243 
Direct transition to Phase IV ‘learning-by-doing’ approaches are controversial and inappropriate for new 244 
VCTs or VCTs with a poor evidence base.13 The history of ITNs and IRS demonstrates varying routes to 245 
establishing effectiveness against malaria disease or infection; ITNs underwent rigorous evaluation 246 
through Phase III RCTs,40 while IRS effectiveness was established decades before evaluation in RCTs.41 247 
Given adequate funding, promising new VCTs should reach approval far faster than ITNs, but depending 248 
on the entomological mode of action, efficacy of a VCT in one ecological setting is not always guaranteed 249 
elsewhere. Recent examples illustrate the importance of demonstrating efficacy against epidemiological 250 
as well entomological outcomes. Topical repellents reduce vector biting, but it took a cluster RCT with 251 
epidemiological outcomes to show their unsuitability as a generalizable public health intervention due to 252 
the high user compliance required.42 Conversely, odour baited traps have recently been shown to reduce 253 
malaria infection prevalence in a rigorous RCT, but entomological data from that study suggest caution 254 
before deploying this VCT at scale in different settings since the traps were largely effective against An. 255 
funestus only.36 Such information may be obtainable through ‘learning-by-doing’ evaluations, as long as 256 
evaluations of outcomes are of high quality. Research institutions will need to support control programs 257 
in design, technical capacity, and analysis to ensure meaningful findings are obtained from Phase IV 258 
effectiveness evaluations.  259 
 260 
Despite limited evidence on their efficacy against malaria, the fourteen VCTs with no complete Phase III 261 
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evaluation offer diverse modes of action to complement those of ITNs and IRS within a comprehensive 262 
intervention package. Some may only be suitable for niche application, for example, insecticide-treated 263 
clothing may be effective for individuals working outdoors at night, but not as a general public health 264 
intervention. Others such as insecticide-treated durable wall linings (which are impregnable with 265 
alternative insecticides to those used for IRS) might reduce reliance on the main classes of insecticides 266 
currently available for ITNs and IRS; a multi-country Phase III evaluation is currently underway.43 267 
Similarly, administration of endectocides such as ivermectin to people or livestock could circumvent 268 
insecticide resistance and target zoophagic behaviours in vectors, although epidemiological effect remains 269 
to be demonstrated.44,45 Some emerging VCTs might reduce transmission by vectors biting outdoors, 270 
including larvicide application by autodissemination using pyriproxyfen, which targets immature 271 
mosquitoes regardless of adult biting and resting behaviour.46 Some emerging VCTs exploit vulnerability 272 
in alternative vector life stages to those targeted by ITNs and IRS. ATSBs, which target sugar feeding, 273 
consistently reduced adult mosquito density and HBR in Phase II studies in Israel, Mali, and the USA. 274 
However, Phase III trials of ATSBs with epidemiological outcomes are certainly needed. Genetic 275 
modification of mosquitoes aims to suppress populations thereby reducing vectorial competence,47 but our 276 
review highlights how such approaches have yet to progress fully beyond laboratory evaluations.  277 
 278 
Overall the expansion of research on supplementary VCTs is encouraging, but arguably the first step to 279 
strengthening vector control for malaria elimination is to improve operational capacity to deliver and 280 
sustain existing interventions effectively.48 For example, major inefficiencies persist within LLIN delivery 281 
systems across SSA, limiting population access.49 There are also opportunities to explore new or 282 
improved delivery mechanisms for existing supplementary interventions, such as larviciding.50 Some 283 
VCTs may not be highly effective individually, but could potentially be highly effective when used in 284 
combinations. Use of mathematical models could help to address such questions, where no 285 
epidemiological evidence is available. Critical to improving vector control is the development of strong 286 
local entomological capacity,51 together with better integration of control across vector-borne diseases and 287 
14 
 
government sectors.48,52  288 
 289 
Our study has several limitations. First, our VCTs of interest were selected a priori through expert 290 
consultation and are not an exhaustive list. Second, our search was restricted to English language papers 291 
only, potentially excluding experiences from some regions. Third, we did not combine data across studies 292 
in a meta-analysis, precluding evaluation of effect on entomological and epidemiological outcomes and 293 
statistical tests for publication bias. Fourth, for studies with entomological outcomes there was no 294 
mechanism to standardize outcomes and assess how heterogeneity in the choice of control affected study 295 
findings. Fifth, this review focused on individual interventions, and did not consider the potential benefits 296 
of combining two or more of the new VCTs in communities already using ITNs and IRS. Finally, we did 297 
not assess methodological quality and risk of bias in Phase I and II studies due to heterogeneity in study 298 
design.  299 
 300 
In conclusion, our review highlights the expanding pipeline of research into new and underutilized 301 
approaches to malaria vector control and the critical need to fund robust evaluation of supplementary 302 
VCTs. Despite substantial gaps in the supporting evidence, several VCTs are promising supplements to 303 
ITNs and IRS. Strengthening operational capacity to implement and evaluate underutilized VCTs, such as 304 
LSM and mosquito-proofed housing, while expanding the evidence base for newer VCTs through 305 
strategic assessment of existing evidence and rigorous epidemiological evaluation, should be central to 306 
global malaria elimination efforts.   307 
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